Does Medicaid cover Mounjaro in Texas?

If you’re considering a GLP-1 medication like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, one of your first questions is likely: Will my insurance cover this? The answer isn’t always straightforward—and for many Americans, it’s becoming more complicated.

GLP-1 receptor agonists have transformed weight management and diabetes care, but their high costs (often over $1,000 per month) mean insurance coverage can make or break access. In 2025, coverage rules vary dramatically depending on whether you have commercial insurance, Medicare, or Medicaid, what state you live in, and whether you’re using the medication for diabetes or weight loss.

This guide breaks down exactly what you need to know about insurance coverage for these breakthrough medications—including recent policy changes, state-by-state Medicaid differences, common denial reasons, and your best options if insurance won’t pay.

Understanding the Coverage Landscape: Why GLP-1s Are Treated Differently

Before diving into specifics, it’s important to understand why these medications face such varied coverage.

The diabetes vs. obesity distinction matters—a lot. Insurance companies generally cover GLP-1 medications when prescribed for Type 2 diabetes (their original FDA-approved use). Ozempic and Mounjaro fall into this category and are typically covered on commercial plans and Medicare Part D as essential diabetes treatments.

However, when the same or similar medications are prescribed specifically for weight loss—like Wegovy (which is literally the same drug as Ozempic, just at a higher dose)—coverage becomes far more restrictive. Many insurers consider anti-obesity medications ‘optional’ benefits that employers can exclude to control costs.

Why the difference? Federal law and insurance regulations treat diabetes as a chronic disease requiring medication coverage, while obesity treatment drugs can be excluded under certain circumstances. This creates a frustrating situation where someone using semaglutide for diabetes gets coverage, but someone using it for obesity (even with serious health risks like heart disease) may not.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance: Coverage with Major Hurdles

What’s Typically Covered

If you have employer-sponsored or individual commercial health insurance:

For diabetes (Ozempic, Mounjaro): Coverage is generally available, though not without requirements. Most plans cover these medications as Tier 3 (non-preferred brand) or Tier 4 (specialty) drugs, meaning you’ll face higher copays or coinsurance—often 20-40% of the drug cost.

For weight loss (Wegovy, Zepbound): This is where it gets tricky. Coverage varies enormously by employer and plan. Many large employers specifically exclude anti-obesity medications from their formularies to control pharmacy spending. According to recent data, a significant portion of commercial plans either don’t cover weight-loss drugs at all or impose strict restrictions that make approval difficult.

Prior Authorization: The Gatekeeper

Nearly all commercial insurers require prior authorization (PA) for GLP-1 medications, whether for diabetes or weight loss. This means your doctor must submit documentation proving you meet specific medical criteria before the insurer will approve coverage.

Typical PA requirements for Wegovy include:

• BMI threshold: Usually ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity like hypertension, type 2 diabetes, or sleep apnea)
• Documented lifestyle intervention: Evidence of at least 6 months of supervised diet and exercise attempts with insufficient weight loss
• Age requirements: Typically 18 years or older (some plans now cover adolescents 12+ if FDA-approved)
• Comorbidity documentation: Medical records showing obesity-related health conditions
• Regular monitoring: Commitment to follow-up visits and demonstration of weight loss progress (often requiring ≥5% body weight reduction after 3-6 months to continue coverage)

For diabetes medications (Ozempic, Mounjaro), PA requirements typically include:

• Confirmed Type 2 diabetes diagnosis
• Evidence of inadequate glycemic control on current therapy
• Often, proof of trying first-line treatments like metformin first (step therapy)
• A1C levels and treatment goals documented

These requirements aren’t merely bureaucratic—they’re designed to limit usage to patients most likely to benefit and to manage costs. The PA process typically takes 5-7 business days, though urgent requests can be expedited.

Common Denial Reasons and How to Fight Them

Understanding why claims get denied can help you prepare a stronger case upfront:

1. Exclusion of weight-loss drugs: If your plan has a blanket exclusion for anti-obesity medications, approval is nearly impossible unless you can demonstrate coverage under a different indication (such as cardiovascular risk reduction, which Medicare now recognizes for Wegovy).

2. Insufficient documentation: Missing records of your supervised weight-loss attempts, incomplete BMI history, or lack of comorbidity documentation will trigger automatic denials.

3. Step therapy not completed: Many insurers require you to try (and document failure of) older, cheaper weight-loss medications or lifestyle programs before approving expensive GLP-1s.

4. Off-label use: Using Ozempic specifically for weight loss when you don’t have diabetes often results in denial, as insurers only cover FDA-approved indications.

If you’re denied, don’t give up. Appeal with:

• Detailed letter of medical necessity from your provider
• Complete medical records showing all criteria are met
• Evidence of health risks if treatment is delayed
• Peer-reviewed studies supporting treatment efficacy for your specific situation

Appeal success rates improve significantly when all documentation is thorough and clearly demonstrates medical necessity.

Medicare Coverage: Limited and Complicated

Medicare Part D does not cover medications prescribed solely for weight loss. This is written into federal law—specifically, Medicare excludes drugs for ‘weight loss or weight gain’ from Part D coverage.

However, there’s an important exception: In 2024, Medicare began covering Wegovy for beneficiaries who have both obesity and established cardiovascular disease. The coverage is specifically for reducing cardiovascular risk in people with obesity and heart disease—not for weight loss as the primary goal. This distinction matters for approval.

For diabetes use:

• Ozempic and Mounjaro are covered under Part D when prescribed for Type 2 diabetes
• They’re typically placed on higher cost-sharing tiers (Tier 3 or specialty tiers)
• Prior authorization is common, requiring documentation of diabetes diagnosis and treatment history

Medicare Advantage plans have slightly more flexibility. Some MA plans in 2025 began offering limited supplemental benefits for weight management, including GLP-1 coverage in very specific circumstances. However, this varies by plan and region.

A critical point for dual-eligible patients: If you have both Medicare and Medicaid, Medicaid may cover weight-loss medications that Medicare won’t—but only in states that choose to cover them, and many states are now cutting this coverage due to budget constraints.

Medicaid Coverage: A Patchwork of State Policies

Medicaid coverage for GLP-1 weight-loss medications is perhaps the most inconsistent and rapidly changing area. As of 2025, only about 13 states provide any coverage for anti-obesity medications through Medicaid—and that number is shrinking.

States Currently Covering Wegovy (with restrictions):

New York continues to cover Wegovy through its NYRx formulary, but with strict prior authorization. Requirements include BMI ≥30 (or ≥27 with comorbidities), documented lifestyle modification attempts, and ongoing monitoring with quantity limits (typically 4 pens per 28 days).

Pennsylvania added coverage in 2023, requiring BMI ≥30 or ≥27 with one weight-related condition, plus documented diet and exercise attempts. However, Pennsylvania announced it will discontinue coverage for weight-loss GLP-1s in January 2026 due to unsustainable budget impacts. If you have diabetes, you must try a diabetes-specific GLP-1 first.

States with No Coverage:

California: In a significant policy reversal, California’s Medi-Cal covered Wegovy with prior authorization through 2025, but coverage ends January 1, 2026 for adults. The state cited budget constraints—spending on these drugs had exploded beyond projections. Pediatric patients under 21 may still access coverage through EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions.

Texas: Texas Medicaid explicitly excludes all obesity medications for adults (age 21+) as of March 2023. Wegovy, Saxenda, and similar drugs are non-covered by rule. Pediatric patients can request exceptions case-by-case.

Florida: Florida Medicaid does not cover any weight-loss medications, utilizing the optional federal exclusion. Only GLP-1s for diabetes (like Ozempic) are covered when prescribed for Type 2 diabetes.

Illinois: Despite expanding coverage for state employees in 2023, Illinois Medicaid does not cover obesity medications as of 2025.

Why the State-by-State Variation?

States have discretion over whether to cover drugs for weight loss and weight gain. While federal Medicaid rules require coverage of most FDA-approved medications, anti-obesity drugs fall into an optional category. The decision comes down to state budgets—and GLP-1s are expensive.

When states do cover these medications, they almost universally require:

• Prior authorization with strict BMI criteria
• Documentation of supervised lifestyle intervention (6+ months)
• Weight-related comorbidities
• Periodic re-evaluation (every 3-6 months)
• Proof of weight loss success to continue coverage

The trend for 2026: More states are likely to restrict or eliminate coverage as budget pressures mount. If you’re currently covered by Medicaid, verify your state’s current policy and prepare for potential changes.

Real-World Cost: What You’ll Actually Pay

Even with insurance coverage, out-of-pocket costs vary dramatically:

With Commercial Insurance:

• Copay with coverage: Typically $50-$300/month depending on your plan’s tier structure and whether you’ve met your deductible
• With manufacturer copay card: Potentially $0-$25/month (Novo Nordisk and Eli Lilly offer savings programs that can reduce copays to nearly zero for commercially insured patients—up to $225/month in savings)
• If plan doesn’t cover: Full cash price, though manufacturer programs can help

With Medicare:

• Part D cost-sharing for diabetes use: Varies by plan; typically 25-33% coinsurance on specialty tier drugs, which could mean $250-$350/month
• For cardiovascular risk reduction: Similar cost-sharing applies
• Once you hit catastrophic coverage: Costs drop significantly (post-$8,000 out-of-pocket in 2025)

With Medicaid:

• If covered: Usually minimal copay ($0-$3 in most states)
• If not covered: No coverage; must pay full price or find assistance

Without Insurance (Self-Pay):

This is where recent changes are making a real difference:

Wegovy:

• List price: ~$1,350/month
• GoodRx new pricing (Nov 2025): $199/month for first two months, then $349/month ongoing
• Novo Nordisk’s cash-pay program: $349/month (down from $499)

Ozempic:

• List price: ~$998/month
• GoodRx pricing: $199/month (first two fills), then $349/month for lower doses; higher 2mg dose ~$499/month
• Standard GoodRx coupons: ~$800-$900

Mounjaro:

• List price: ~$1,080/month
• Standard coupons: ~$1,000
• Eli Lilly’s Mounjaro savings card: $25/month with commercial insurance (for diabetes)

Zepbound (tirzepatide for weight loss):

• Lilly’s self-pay program: $299-$449/month for single-dose vials (launched Dec 2025)

These new pricing programs represent a 60-70% discount from list prices, making self-pay much more accessible than it was even six months ago.

Patient Assistance Programs: Free Medication for Those Who Qualify

If you’re uninsured or underinsured and can’t afford even the discounted prices, patient assistance programs (PAPs) may provide free medication:

Novo Nordisk’s PAP:

• Provides Wegovy or Ozempic at no cost
• Requirements: Uninsured or underinsured, household income typically <400% of federal poverty level (around $60,000 for individuals, $124,000 for family of four in 2025)
• Application through provider or NovoCare

Eli Lilly’s PAP:

• Similar income requirements
• Covers Mounjaro, Zepbound for those who qualify
• Free supply typically provided for 12 months, renewable

These programs can be lifesaving for patients who meet criteria but require documentation and physician participation.

How Klarity Health Can Help Navigate Coverage

The complexity of insurance coverage for GLP-1 medications can feel overwhelming. This is where Klarity Health’s approach offers real value.

Transparent pricing from the start: Unlike many telehealth platforms, Klarity provides upfront information about costs—both what your insurance might cover and what you’ll pay if it doesn’t. This transparency lets you make informed decisions without surprises at the pharmacy.

Flexible payment options: Klarity accepts both insurance and cash pay, meaning you’re not locked into one approach. If your insurance denies coverage, you can pivot to self-pay with manufacturer programs or discount cards without starting over with a new provider.

Provider availability: Getting the prior authorization documentation right requires an engaged provider. Klarity’s healthcare professionals are experienced with insurance requirements and can help compile the necessary documentation for PA requests and appeals.

Continuity of care: Whether you’re navigating initial approval, appealing a denial, or transitioning between insurance and self-pay, having consistent provider support matters. Klarity’s model of accessible, ongoing care helps you stay on track with treatment even when coverage situations change.

The reality is that insurance coverage for these medications remains challenging—but having a provider who understands the system and can adapt to your specific situation significantly improves your chances of accessing treatment.

What If Your Insurance Won’t Cover It? Your Action Plan

If you’ve been denied or your insurance doesn’t cover GLP-1 weight-loss medications:

1. Verify the reason for denial or exclusion

• Is it a plan exclusion or a PA denial?
• If PA denial, what specific criteria weren’t met?

2. Consider an appeal with additional documentation

• Work with your provider on a detailed letter of medical necessity
• Include all required medical records
• Emphasize health risks and comorbidities

3. Explore manufacturer savings programs

• Novo Nordisk and Eli Lilly copay cards (if you have some insurance)
• Patient assistance programs if uninsured and income-eligible
• New reduced self-pay pricing ($199-$349/month programs)

4. Look into alternative funding

• Flexible Spending Account (FSA) or Health Savings Account (HSA) funds
• Payment plans through pharmacies or telehealth providers
• Nonprofit assistance programs focused on obesity treatment

5. Consider clinically appropriate alternatives

• Older, less expensive weight-loss medications (phentermine, orlistat)
• Clinical trials offering free medication
• Comprehensive lifestyle programs (sometimes covered as preventive care)

6. Re-evaluate annually

• Insurance benefits change with plan years
• Your employer might add coverage
• Medicaid policies in your state could expand

Telehealth and Insurance: What You Need to Know

One bright spot: telehealth visits for weight management are generally covered by insurance when in-person visits would be. Over 40 states have enacted telehealth parity laws requiring insurers to cover virtual care equivalently to in-office visits.

This means:

• Virtual consultations with providers for weight-loss treatment are typically covered
• Nutritional counseling (an ACA-mandated preventive service for obesity) can be done via telehealth
• Follow-up monitoring required for PA approval can often be conducted virtually

Important considerations:

• Verify the telehealth provider is in-network (or out-of-network benefits apply)
• Most insurers require live video (not just phone or messaging)
• The visit itself being covered doesn’t guarantee medication coverage—those are separate decisions

For many patients, telehealth actually improves access to the regular monitoring that insurers require for ongoing coverage approval.

The Bottom Line: Coverage Is Possible but Requires Persistence

Does insurance cover Wegovy, Ozempic, or Mounjaro? The answer is: it depends—on your insurance type, your state, the indication, and your willingness to navigate a complex approval process.

What’s clear in 2025:

• Coverage for diabetes use (Ozempic, Mounjaro) is generally available but requires prior authorization
• Coverage for weight-loss use (Wegovy, Zepbound) is inconsistent and often denied
• Medicare doesn’t cover weight loss (except for cardiovascular risk reduction)
• Medicaid coverage is shrinking as states cut programs
• Self-pay options have improved dramatically with new pricing programs

Your best strategy:

1. Start with a thorough insurance check: Confirm your plan’s formulary and PA requirements before beginning treatment
2. Work with an experienced provider: Someone who knows how to document cases for insurance approval
3. Prepare for appeals: First denials aren’t final—many are overturned with proper documentation
4. Have a backup plan: Know your self-pay options and assistance programs
5. Stay informed: Coverage policies are changing rapidly; what’s true today may change by next year

The landscape is challenging, but access is improving. Manufacturer price cuts, new discount programs, and growing recognition of obesity as a chronic disease are slowly shifting the conversation. In the meantime, working with providers who understand both the clinical and coverage sides of treatment—like those at Klarity Health—can make all the difference in actually getting the medication you need.

Ready to explore your options? Whether you have insurance coverage or need to navigate self-pay options, Klarity Health’s providers can help you understand your specific situation and create a treatment plan that works with your coverage—or without it. With transparent pricing, flexible payment options, and experienced healthcare professionals, you can focus on your health goals instead of insurance headaches.

Frequently Asked Questions

Will my insurance cover Wegovy if I have a BMI of 28 with high blood pressure?

Many commercial plans will cover Wegovy with a BMI ≥27 if you have at least one weight-related comorbidity like hypertension. However, you’ll typically also need to document 6 months of supervised lifestyle modification attempts and meet other prior authorization criteria. Medicare and many Medicaid programs won’t cover it at all for weight loss, regardless of BMI.

Can I use Ozempic for weight loss if my insurance covers it for diabetes?

If you have Type 2 diabetes, your insurance will cover Ozempic for that indication. However, if you’re using it primarily for weight loss and don’t have diabetes, most insurers will deny coverage as off-label use. Your provider must prescribe it for an approved indication for coverage to apply.

What happens if my state Medicaid stops covering Wegovy while I’m on it?

If you’re currently receiving Wegovy through Medicaid and your state discontinues coverage (as California and Pennsylvania are doing in January 2026), you’ll typically receive advance notice. You may need to transition to self-pay options, manufacturer assistance programs, or work with your provider to find alternative treatments. Contact your Medicaid case manager as soon as you’re notified of coverage changes.

How long does the prior authorization process take?

Most insurers respond to PA requests within 5-7 business days for non-urgent requests. If denied, the appeals process can take an additional 2-3 weeks. To speed things up, ensure all required documentation is submitted upfront and follow up regularly with both your provider and insurance company.

Are there any alternatives if I can’t afford GLP-1 medications even with discount programs?

Yes. Older weight-loss medications like phentermine or orlistat cost $30-$100/month and may be covered by insurance. You can also explore comprehensive lifestyle programs (often covered as preventive care), clinical trials offering free medication, or patient assistance programs if you meet income requirements. Your provider can help identify the most appropriate and accessible option for your situation.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

Top 5 Sources:

1. California DHCS Medi-Cal Coverage Update (December 2025) – www.cmadocs.org – Official state announcement of GLP-1 coverage termination effective January 1, 2026

2. GoodRx New Pricing Program Launch (November 17, 2025) – www.businesswire.com – Announces $199/month introductory pricing for Wegovy and Ozempic with Novo Nordisk partnership

3. Novo Nordisk Self-Pay Price Reductions (November 2025) – www.fiercepharma.com – Details manufacturer’s reduction of cash-pay prices to $349/month for Wegovy/Ozempic

4. KFF Medicaid Coverage Analysis (November 2024) – www.kff.org – Comprehensive survey showing only 13 states cover obesity medications through Medicaid with federal exclusion details

5. Pennsylvania Medicaid Coverage Announcement (December 2024/August 2024) – www.phlp.org and www.wesa.fm – Details PA’s coverage criteria and announcement of January 2026 coverage termination

All pricing, coverage policies, and formulary information verified as of December 17, 2025. Insurance policies and state Medicaid programs may change; always verify current coverage with your specific plan.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499